safe: cardiotoxicity prevention in breast cancer treated with anthracyclines and/or trastuzumab
Published 1 year ago • 174 plays • Length 1:47Download video MP4
Download video MP3
Similar videos
-
2:01
beyond anthracyclines and trastuzumab: cardiotoxicity of novel agents
-
2:44
safe: cardioprotective strategy for non-metastatic bc patients receiving anthracycline-based chemo
-
3:26
subgroup analysis from safe trial: pharmacological cardioprotective strategies for breast cancer
-
1:34
cardiac toxicity in patients with breast cancer
-
40:04
jacc: cardiooncology video case presentation: cardiotoxicity during her2-targeted therapy
-
2:22
dr. tripathy on the treatment of breast cancer with anthracyclines and trastuzumab
-
3:20
dr. hurvitz on eliminating anthracyclines in her2 breast cancer treatment
-
10:01
cardio-oncology a-z: breast cancer treatment related cardiotoxicity with dr anne blaes
-
12:03
anthracycline chemotherapy side effects: cardiotoxicity in breast cancer explained
-
4:30
esc guidelines in cardio-oncology
-
7:32
cardiac safety in the aphinity study
-
55:08
cardiac toxicities of breast cancer treatment: pathophysiology, prevention, and treatment
-
58:50
cardiac dysfunction in breast cancer patients: monitoring, diagnosis, and treatment
-
20:56
cardiovascular recovery in anthracycline cardiotoxicity
-
1:55
investigating anthracycline, taxane and trastuzumab-based neoadjuvant chemotherapy in her2 ebc
-
2:43
lilac: comparing cardiac safety of abp 980 with trastuzumab
-
1:01
anthracycline cardiotoxicity
-
1:47
her2climb-05: tucatinib trastuzumab and pertuzumab as maintenance therapy for her2 metastatic bc
-
0:48
evaluating the safety of t-dxd with radiotherapy in her2 metastatic breast cancer